Hainsworth, John D <br/><br/>
Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy.  [electronic resource] 

 -  Breast cancer research and treatment  11 2016 
 - 41-49 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1573-7217 
<br/><br/><label>Standard No.: </label>10.1007/s10549-016-3969-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Immunological--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biomarkers, Tumor<br/>Breast Neoplasms--diagnosis<br/>Drug Resistance, Neoplasm--genetics<br/>Female<br/>Gene Expression<br/>Humans<br/>Immunoassay--methods<br/>Middle Aged<br/>Models, Biological<br/>Molecular Targeted Therapy<br/>Neoplasm Metastasis<br/>Neoplasm Staging<br/>Neoplastic Cells, Circulating--metabolism<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>Retreatment<br/>Signal Transduction--drug effects<br/>Treatment Outcome